BMO Money Market Fund (ZMMK) News

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage...

Form 8-K - Current report

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

PHILADELPHIA, May 29, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first...

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage...

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – –...

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis

PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities